Background: Increasing evidence points to beta-cell regeneration in individuals with
| INTRODUC TI ON
Type 1 diabetes mellitus (type 1 DM) is characterized by an autoimmune mediated process which leads to the destruction of insulinproducing beta cells. 1 Hyperglycaemia develops as a consequence of the gradual loss of beta cells. Until recently, it was assumed that all insulin-producing cells are being destroyed over the course of the disease. Our group and others have shown that even years after diagnosis of type 1 DM, viable beta cells are present and able to secrete at least low amounts of insulin. 2, 3 Since residual beta-cell function prevents complications such as retinopathy, nephropathy and hypoglycaemia, 4 it is of great interest to preserve and enhance the function of these remaining insulin-producing cells.
Whether beta-cell replication exists in adults is still controversial. 5, 6 Increasing evidence suggests that beta-cell differentiation and regeneration occur throughout the course of the disease. [7] [8] [9] Several hormones have been implicated in this process, in particular the gut hormone glucagon-like peptide-1 (GLP-1). 10 GLP-1 is acutely released from intestinal L cells in response to nutrient ingestion and from pancreatic alpha cells, especially during metabolic stress [11] [12] [13] and improves glucose homeostasis. Drugs such as dipeptidyl-peptidase IV (DPP-IV) inhibitors, which inhibit the degradation of GLP-1, are widely used for treatment of type 2 diabetes mellitus (type 2 DM).
14 Similar to GLP-1, physical exercise is known to ameliorate glucose control in type 2 DM. 15, 16 We have previously shown that GLP-1 plays an important role in the exercise-induced improvement of glucose homeostasis in mice. 17 Physical exercise led to release of interleukin-6 (IL-6) from skeletal muscle, which triggered GLP-1 secretion and subsequently led to an improvement in insulin secretion and glucose homeostasis. Based on these findings, we hypothesized that in individuals with type 1 DM, residual beta-cell function would improve with exercise via IL-6-dependent up-regulation of GLP-1.
We further explored whether the combination of exercise and treatment with a DPP-IV inhibitor would amplify this endocrine loop in people with long-lasting type 1 DM. 
| MATERIAL S AND ME THODS

| Study design and participants
| Randomization and treatment
All participants received sitagliptin (Januvia ® ; MSD Merck Sharp & Dohme AG) 100 mg per os (po) once daily and were randomized in a 1:1 ratio to complete a 12-week exercise intervention or to continue physical activity on their pre-existent level. Randomization was performed by an external statistician.
| Study assessment
All participants had a screening visit and four study visits. and determine the exercise load for the exercise intervention group.
Participants of the exercise intervention were given instructions for an unsupervised bicycle training consisting of 5-minute warm-up followed by 45 minutes at 75% VO 2 max and 5-minute cool-down for at least three times a week on top of their pre-existent physical activity level. Heart rate monitors (Polar Watch; Polar) were dispensed to participants in the intervention group to be worn during each exercise session. Adherence to the exercise target was evaluated by the read-outs of the heart rate monitor. Daily used insulin dose at baseline and after the intervention was documented during 3 days with insulin diaries. Sitagliptin treatment was initiated after completion of the MMTT and VO 2 max test on the first day of the study. All 
| Study end-points
The primary end-point was change in the area under the concentration-time curve (AUC) of C-peptide during a MMTT at baseline and after 12 weeks with or without an exercise intervention. Predefined secondary end-points were change in glucose, HbA1c, insulin sensitivity, insulin requirements, total GLP-1, change in lipids profile, hsCRP, creatine kinase (CK).
| Statistical analysis
The sample size of 12 participants per group was based on the assumption of a 30% change in beta-cell function in response to a physiological stimulus as compared to baseline, providing 90% power and P < 0.05.
The primary analysis followed the intention to treat principle, that is, participants with complete follow-up were analysed in the groups to which they were randomized. The AUC C-peptide over 120 minutes during the MMTT was calculated using the trapezoid rule. P-value < 0.05 was defined as significant. Data were analysed using GraphPad Prism Vers 7 (GraphPad Software Inc).
| RE SULTS
A total of 33 individuals were screened, five did not meet inclusion or exclusion criteria. Twenty-eight people were enrolled in the study, and four withdrew their consent. One participant in the exercise intervention group dropped out after randomization due to a prolonged upper respiratory tract infection. Twenty-three participants completed the study (Figure 1) . Baseline characteristics were similar in both groups, apart from VO 2 max, which was slightly higher in the exercise group (Table 1) .
After a 12-week intervention, there was no difference in the change of AUC C-peptide between groups (P = 0.09) ( Table 2 , Figure 2 ). Interestingly, there was an increase in AUC C-peptide after a 12-week treatment period as compared to baseline in the group with sitagliptin only, but it did not reach statistical significance (P = 0.07, Figure S1 ). There was no change in AUC glucose between the two groups (P = 0.23) (Figure 2 ). Change in fasting glucose (P = 0.52), HbA1c (P = 0.79), insulin sensitivity (P = 0.45), daily insulin use (P = 0.32), AUC total GLP-1 (P = 0.78) did not differ between groups (Table 2 ). hsCRP was similar in both groups (P = 0.73). Interestingly, high-density lipoprotein cholesterol (HDL-C) improved in the exercise intervention group (P = 0.04), while change in total cholesterol (P = 0.83), low-density lipoprotein cholesterol (LDL-C) (P = 0.19) and triglycerides (P = 0.11) remained similar between groups (Table 2, Figure 3 ).
Weight decreased in both groups, and the difference between groups was not significant ( Table 2 ). Systolic and diastolic blood pressure as well as heart rate did not change in both groups (Table 2) .
TA B L E 2 Comparison of change before and after 12 wk intervention between treatment groups
Change in CK tended to be higher in the exercise intervention group, but did not reach significance (P = 0.17) ( Table 2 ).
Change in VO 2 max was not different between groups (P = 0.97) ( Table 2 ). Training compliance in the exercise intervention group was as follows: four participants (36.3%) completed an average of ≥3 sessions per week, 5 (45.4%) completed at least 2-2.9 sessions per week, 2 (18.1%) trained 1-1.9 times per week. Seven participants (64%) accomplished at least 50% of the training sessions at 75% of VO 2 max during for at least 25 minutes of training.
The number of adverse events was similar in both groups (Table 3 ). The most frequent adverse event was a common cold (seven adverse events in each group). 
E TH I C A L S TATEM ENT
This study was approved by the regional ethical committee (EKBB 349/12) and Swissmedic. Informed consent was obtained from all participants. 
TA B L E 3 Adverse events
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